IGC Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
IGC NYSE American 2830 igcpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IGC Pharma, Inc.

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia - Jan 12th, 2026 7:00 am
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Jan 6th, 2026 6:00 am
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - Jan 5th, 2026 7:00 am
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum - Dec 19th, 2025 7:00 am
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines - Dec 15th, 2025 7:00 am
Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says - Dec 13th, 2025 9:15 am
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Dec 10th, 2025 7:00 am
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Dec 9th, 2025 7:00 am
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease - Dec 2nd, 2025 7:00 am
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Nov 25th, 2025 7:00 am
IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers - Nov 17th, 2025 4:00 pm
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital - Nov 17th, 2025 6:30 am
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates - Nov 14th, 2025 3:30 pm
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates - Nov 13th, 2025 3:20 pm
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders - Nov 13th, 2025 7:00 am
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - Nov 12th, 2025 3:15 pm
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates - Nov 10th, 2025 3:20 pm
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025 - Nov 10th, 2025 7:00 am
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 5:10 am
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline - Nov 3rd, 2025 6:52 am